More evidence for Aimovig's favorite tag in migraine tussle

23 October 2018
2019_biotech_test_vial_discovery_big

The race to grab market share in the migraine space is becoming one of the most keenly-watched in pharma – and Aimovig (erenumab) is  forecast to be the top-selling drug by 2026.

Novartis (NOVN: VX) and US biotech major Amgen (Nasdaq: AMGN), which are co-commercializing Aimovig in the USA, will feel even more confident in its prospects after The Lancet published full data from the LIBERTY study.

This trial was the first study of a calcitonin gene-related peptide (CGRP) receptor antagonist in a patient population where multiple treatments had previously failed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology